Molecular profiling of breast cancer: clinical implications

Breast cancers are routinely subcategorised on the basis of clinical stage, cellular morphology and immunohistochemical analysis of a small number of markers. The recent development of gene expression microarray and related technologies provides an opportunity to perform more detailed profiling of the disease. It is anticipated that the molecular classification arising from such studies will be more powerful than its pathological predecessor at confining treatment to those patients who are most likely to benefit. It is likely that this will result in a much less frequent use of adjuvant chemotherapy. Furthermore, of those who do receive it, a higher proportion will benefit. If adopted, this will offer considerable patient benefits in terms of reducing unnecessary toxicity and have major health economic implications.

[1]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Mansel,et al.  A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma , 1996, Histopathology.

[3]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[4]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[5]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Schulze,et al.  Navigating gene expression using microarrays — a technology review , 2001, Nature Cell Biology.

[7]  Partha S. Vasisht.  Computational Analysis of Microarray Data , 2003 .

[8]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[11]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[12]  J. Nährig,et al.  Chromosomal Imbalances are Associated with Metastasis-Free Survival in Breast Cancer Patients , 2002, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[13]  Fuad G. Gwadry,et al.  Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells , 2003, Genome Biology.

[14]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[15]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[16]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[17]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[18]  C. Sotiriou,et al.  Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer , 2002, Breast Cancer Research.

[19]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[20]  J. Stec,et al.  Emerging science: Prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer , 2003 .

[21]  René Bernards,et al.  A progression puzzle. , 2002, Nature.

[22]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[23]  L. Lipton,et al.  Preoperative/neoadjuvant medical therapy for early breast cancer. , 2001, The Lancet. Oncology.

[24]  M. Dowsett,et al.  The biology of neoadjuvant chemotherapy for breast cancer. , 2002, Endocrine-related cancer.

[25]  J. Houghton.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomized controlled trial , 2003, The Lancet.

[26]  H. Höfler,et al.  Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH , 2000, International journal of cancer.